What is the recommended treatment for sickle cell anemia?

Treatment of Sickle Cell Anemia

Hydroxyurea is the first-line disease-modifying therapy for sickle cell anemia and should be initiated in all children starting at 9 months of age regardless of symptoms, and in adults with frequent pain crises, acute chest syndrome, or severe anemia interfering with daily activities. 1, 2

Disease-Modifying Pharmacotherapy

Hydroxyurea (First-Line Therapy)

• Initiate hydroxyurea in infants from 9 months of age, including asymptomatic children, as this reduces morbidity and mortality long-term 1, 3
• For adults, strongly recommend hydroxyurea when patients experience:
  • Three or more severe vasoocclusive crises in any 12-month period 1
  • Pain or chronic anemia interfering with daily activities 1
  • Severe or recurrent acute chest syndrome episodes 1
• Hydroxyurea works by increasing fetal hemoglobin, reducing leukocyte/platelet counts, decreasing endothelial adhesion molecule expression, and increasing nitric oxide levels 3
• Contraindicated during pregnancy and lactation due to teratogenic effects, though may be considered in high-risk patients during second and third trimesters 3

Additional FDA-Approved Therapies (Adjunctive/Second-Line)

• L-glutamine: Reduces hospitalization rates by 33% and decreases mean hospital length of stay from 11 to 7 days 2
• Crizanlizumab: Reduces pain crises from 2.98 to 1.63 per year by preventing cell adhesion and hemoglobin sickling 2, 4
• Voxelotor: Increases hemoglobin by at least 1 g/dL in 51% of patients (vs 7% placebo) by improving hemoglobin oxygen-binding capacity 2, 4

Preventive Care Measures

Infection Prevention

• Daily oral prophylactic penicillin up to age 5 years (strong recommendation) 1

Stroke Prevention

• Annual transcranial Doppler examinations from ages 2 to 16 years in children with sickle cell anemia 1
• Long-term transfusion therapy for children with abnormal transcranial Doppler velocity (≥200 cm/s) to prevent stroke (strong recommendation) 1

Transfusion Support

Acute Complications

• For severe acute chest syndrome: Use automated or manual red cell exchange over simple transfusions 5
• For moderate acute chest syndrome: Automated RCE, manual RCE, or simple transfusions are all acceptable options 5
• Automated RCE is preferred over manual RCE when available, as it more rapidly reduces HbS levels 5

Chronic Transfusion Therapy

• Preoperative transfusion to increase hemoglobin to 10 g/dL is strongly recommended 1
• Maintain sickle hemoglobin levels <30% prior to next transfusion during long-term therapy 1
• Monitor iron overload with validated R2, T2*, or R2* MRI methods for liver iron content 5
• Initiate iron chelation therapy when indicated by iron burden assessment 1

Acute Pain Management

• Rapid initiation of opioids for severe pain associated with vasoocclusive crisis (strong recommendation) 1
• Use incentive spirometry in patients hospitalized for vasoocclusive crisis 1
• Patients with sickle cell disease are not more likely to develop addiction to pain medications than the general population 2

Hematopoietic Stem Cell Transplantation (Curative Therapy)

Indications for Matched Sibling Donor HSCT

• For neurologic injury: Consider transplantation in all patients with a matched related sibling donor, particularly children <16 years who have better outcomes 5
• For frequent pain: Use matched allogeneic transplantation in patients who do not respond to hydroxyurea, new targeted therapies, or chronic transfusion 5
• For recurrent acute chest syndrome: Use matched related allogeneic transplantation in patients with continued episodes despite optimal standard care 5

HSCT Technical Considerations

• Perform transplantation at earlier age rather than older age when indicated 5
• For children with matched sibling donor: Use myeloablative conditioning over reduced-intensity conditioning 5
• For adults with matched sibling donor: Use nonmyeloablative conditioning over reduced-intensity conditioning 5
• Use HLA-identical sibling cord blood when available (with adequate cell dose and viability) over bone marrow 5
• For patients lacking matched sibling donor: Consider alternative donor transplants only in context of clinical trial 5
• HSCT achieves >90% cure rates in short-term follow-up but is limited by donor availability (only 20% have matched sibling donors) 5

Management of Chronic Complications

• For avascular necrosis: Use analgesics and physical therapy 1
• For microalbuminuria in adults: Use ACE inhibitor therapy 1
• For proliferative sickle cell retinopathy: Refer to expert specialists for laser photocoagulation consideration 1
• For signs of pulmonary hypertension: Perform echocardiography evaluation 1

Common Pitfalls

The major pitfall is underutilization of hydroxyurea—it remains the cornerstone therapy but is frequently not prescribed despite strong evidence for mortality and morbidity reduction 1, 2. Another critical error is delaying HSCT evaluation in eligible patients with matched sibling donors, as outcomes are superior at younger ages 5. Finally, inadequate pain management due to unfounded addiction concerns compromises quality of life, as addiction rates in sickle cell patients mirror the general population 2.